IBA develops, manufactures and supports medical devices and software solutions for cancer treatment by proton beam therapy, for cancer diagnosis and for patient quality assurance (Dosimetry).
In addition, the company partners with healthcare leaders to provide cancer clinics and academic health centers with a fully-integrated approach of the patient flow. Today, IBA solutions in oncology are used in over 3,000 hospitals worldwide.
Its expertise in particle accelerators enables IBA to provide also sterilization and ionization solutions for the industry. Headquartered in Belgium, IBA operates in more than 40 countries in North America, Europe & Asia. IBA is listed on the pan-European stock exchange EURONEXT.
*IBA Molecular is a joint venture company between IBA and SK Capital Partners in which IBA owns a 40% stake.